+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery



Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery



Journal of Biomolecular Screening 13(5): 343-353



The potential for metabolism-related drug-drug interactions by new chemical entities is assessed by monitoring the impact of these compounds on cytochrome P450 (CYP) activity using well-characterized CYP substrates. The conventional gold standard approach for in vitro evaluation of CYP inhibitory potential uses pooled human liver microsomes (HLM) in conjunction with prototypical drug substrates, often quantified by LC-MS/MS. However, fluorescent CYP inhibition assays, which use recombinantly expressed CYPs and fluorogenic probe substrates, have been employed in early drug discovery to provide low-cost, high-throughput assessment of new chemical entities. Despite its greatly enhanced throughput, this approach has been met with mixed success in predicting the data obtained with the conventional gold standard approach (HLM+LC-MS). The authors find that the predictivity of fluorogenic assays for the major CYP isoforms 3A4 and 2D6 may depend on the quality of the test compounds. Although the structurally more optimized marketed drugs yielded acceptable correlations between the fluorogenic and HLM+LC-MS/MS assays for CYPs 3A4, 2D6, and 2C9 (r2 = 0.5-0.7; p < 0.005), preoptimization, early discovery compounds yielded poorer correlations (r2 < or = 0.2) for 2 of these major isoforms, CYPs 3A4 and 2D6. Potential reasons for the observed differences are discussed.

(PDF emailed within 0-6 h: $19.90)

Accession: 053072019

Download citation: RISBibTeXText

PMID: 18474896

DOI: 10.1177/1087057108317480


Related references

Mass Spectrometry Based Assays for Drug Screening in the Early Phases of Drug Discovery. Frontiers in Medicinal Chemistry - Online 1(1): 273-292, 2004

Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Analytical Biochemistry 332(1): 153-159, 2004

Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabolism and Drug Interactions 21(3-4): 163-185, 2006

Automatic mass spectrometry method development for drug discovery: application in metabolic stability assays. Rapid Communications in Mass Spectrometry 18(24): 3105-3112, 2004

Evaluation of laser diode thermal desorption (LDTD) coupled with tandem mass spectrometry (MS/MS) for support of in vitro drug discovery assays: increasing scope, robustness and throughput of the LDTD technique for use with chemically diverse compound libraries. Journal of Pharmaceutical and Biomedical Analysis 59: 18-28, 2012

Leveraging the contribution of thermodynamics in drug discovery with the help of fluorescence-based thermal shift assays. Journal of Biomolecular Screening 16(5): 552-556, 2011

Development of a low volume plasma sample precipitation procedure for liquid chromatography/tandem mass spectrometry assays used for drug discovery applications. Rapid Communications in Mass Spectrometry 19(15): 2131-2136, 2005

Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. International Journal of Pharmaceutics 335(1-2): 1-11, 2006

Ligand-based drug discovery against RNA using mass spectrometry. Abstracts of Papers American Chemical Society 221(1-2): MEDI 216, 2001

Lead discovery for microsomal prostaglandin E synthase using a combination of high-throughput fluorescent-based assays and RapidFire mass spectrometry. Journal of Biomolecular Screening 17(5): 641-650, 2012

Native Mass Spectrometry in Fragment-Based Drug Discovery. Molecules 21(8): -, 2017

Mass spectrometry-based proteomics in preclinical drug discovery. Chemistry & Biology 19(1): 72-84, 2012

The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery. Current Topics in Medicinal Chemistry 1(5): 463-471, 2002

Strategic use of affinity-based mass spectrometry techniques in the drug discovery process. Analytical Chemistry 74(1): 1-9, 2002

Applications of mass spectrometry in early stages of target based drug discovery. Journal of Pharmaceutical and Biomedical Analysis 40(3): 528-538, 2005